![Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1. - Abstract - Europe PMC Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1. - Abstract - Europe PMC](https://europepmc.org/articles/PMC5464773/bin/elife-25541-fig8-figsupp2.jpg)
Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1. - Abstract - Europe PMC
![Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1 | eLife Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1 | eLife](https://iiif.elifesciences.org/lax/25541%2Felife-25541-fig4-v1.tif/full/,1500/0/default.jpg)
Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1 | eLife
![Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1. - Abstract - Europe PMC Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1. - Abstract - Europe PMC](https://europepmc.org/articles/PMC5464773/bin/elife-25541-fig5-figsupp1.jpg)
Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1. - Abstract - Europe PMC
![Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1 | eLife Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1 | eLife](https://iiif.elifesciences.org/lax/25541%2Felife-25541-fig7-figsupp1-v1.tif/full/1500,/0/default.jpg)
Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1 | eLife
![Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1 | eLife Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1 | eLife](https://iiif.elifesciences.org/lax/25541%2Felife-25541-fig2-figsupp1-v1.tif/full/,1500/0/default.jpg)
Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1 | eLife
![Anniversary: 75 years ago PUMA founder Rudolf Dassler registered the "Rudolf Dassler Sportfabrik" (RUDA) - PUMA CATch up Anniversary: 75 years ago PUMA founder Rudolf Dassler registered the "Rudolf Dassler Sportfabrik" (RUDA) - PUMA CATch up](https://www.puma-catchup.com/wp-content/uploads/2023/01/PUMA_75_H-1.jpg)
Anniversary: 75 years ago PUMA founder Rudolf Dassler registered the "Rudolf Dassler Sportfabrik" (RUDA) - PUMA CATch up
![Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1 | eLife Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1 | eLife](https://iiif.elifesciences.org/lax/25541%2Felife-25541-fig1-v1.tif/full/,1500/0/default.jpg)